Diametric Capital LP trimmed its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 53.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,487 shares of the company's stock after selling 35,423 shares during the quarter. Diametric Capital LP's holdings in Indivior were worth $391,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Indivior in the fourth quarter valued at $359,000. Stifel Financial Corp acquired a new stake in Indivior in the 3rd quarter valued at about $100,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Indivior in the 4th quarter valued at about $1,192,000. XTX Topco Ltd grew its position in shares of Indivior by 763.4% during the third quarter. XTX Topco Ltd now owns 133,194 shares of the company's stock worth $1,299,000 after buying an additional 117,767 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in Indivior in the third quarter valued at approximately $536,000. 60.33% of the stock is owned by institutional investors and hedge funds.
Indivior Stock Down 2.5 %
Indivior stock traded down $0.23 during mid-day trading on Friday, hitting $9.15. The company had a trading volume of 1,504,792 shares, compared to its average volume of 913,748. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $21.64. The business has a fifty day moving average of $9.98 and a 200 day moving average of $10.37. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -26.14 and a beta of 0.93.
Indivior (NASDAQ:INDV - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported $0.32 EPS for the quarter, meeting analysts' consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. Equities analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have commented on INDV. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler lowered their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Finally, Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock.
Check Out Our Latest Stock Analysis on Indivior
Indivior Profile
(
Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
